YOLFTbeta
TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc.

TLSI · NASDAQ · Healthcare / Medical Devices

2.43USD-0.09 (-3.57%)

Price History

Full chart

Market Stats

Previous Close2.52
Open2.61
Day Range2.23 – 2.67
52-Week Range2.20 – 7.95
Volume403.86K
Market Cap270.31M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.35
Dividend Yield0.00%
Beta0.44
50-Day Avg4.89
200-Day Avg4.74

About

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMs. Mary T. Szela B.S.N., M.B.A.
  • Employees102
  • Headquarters6272 West 91st Avenue, Westminster, CO, United States, 80031, USA
  • Websitehttps://trisaluslifesci.com

Leadership

  • Ms. Mary T. Szela B.S.N., M.B.A.CEO, President & Director · b. 1964
  • Mr. David B. PatienceChief Financial Officer · b. 1986
  • Dr. Richard B. Marshak M.B.A., VMDChief Commercial Officer · b. 1959
  • Andrea MarassoVice President of Marketing
  • Ms. Jennifer L. Stevens J.D.Chief Regulatory, Quality and Therapeutics Officer · b. 1962
  • Dr. Bryan F. Cox Ph.D.Chief of Research · b. 1962
  • Dr. Richard Marshall M.D.Chief Medical Officer

Financials

Income Statement

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue8.40M12.40M18.51M29.43M45.15M
Growth (%)-+47.58%+49.31%+58.99%+53.41%
Cost of Revenue1.19M2.26M2.60M4.10M6.96M
Gross Profit7.21M10.14M15.91M25.33M38.19M
Gross Margin85.80%81.79%85.93%86.06%84.57%
Operating Expense31.24M46.58M70.38M61.49M65.13M
Operating Income-24.03M-36.44M-54.48M-36.16M-26.95M
Operating Margin-286.06%-293.91%-294.28%-122.88%-59.68%
EBITDA-26.62M-46.76M-58.65M-32.38M-33.05M
EBITDA Margin-316.83%-377.18%-316.86%-110.04%-73.20%
Net Income-28.84M-47.19M-59.36M-33.23M-39.23M
Net Income Margin-343.35%-380.60%-320.69%-112.92%-86.88%
R&D14.22M21.36M29.84M17.69M14.96M
R&D as % of Total Revenue169.31%172.27%161.17%60.10%33.14%
Interest Expense1.76M1.00K16.00K3.09M5.54M
Interest Expense % of Total Revenue20.96%0.01%0.09%10.50%12.28%

Balance Sheet

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets37.84M22.00M24.60M23.97M35.33M
Total Liabilities6.93M34.32M51.66M49.87M69.19M
Total Equity30.90M-12.32M-27.07M-25.89M-33.86M
Cash30.30M9.41M11.78M8.53M20.44M
Total Debt42.18M1.96M1.59M23.63M34.44M
Net Debt-30.30M-7.45M-10.18M15.10M14.00M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-677.60K-22.70M-32.31M-50.58M-40.84M-18.01M
Investing Cash Flow--2.26M-1.79M-1.59M-345.00K-838.00K
Financing Cash Flow252.01M50.77M13.46M54.63M37.94M30.76M
Capital Expenditure545.00K1.26M786.00K588.00K345.00K918.00K
Free Cash Flow-1.22M-23.95M-33.10M-51.17M-41.19M-18.93M
FCF to OCF180.43%105.54%102.43%101.16%100.84%105.10%

Earnings

Report DateJun 28, 2021Aug 16, 2021Nov 12, 2021Mar 3, 2022May 11, 2022Aug 10, 2022Nov 10, 2022Mar 22, 2023Mar 31, 2023Aug 30, 2023Nov 14, 2023Dec 31, 2023May 15, 2024Aug 14, 2024Nov 14, 2024Mar 27, 2025May 15, 2025Aug 12, 2025Nov 13, 2025Mar 5, 2026May 13, 2026Aug 6, 2026Nov 12, 2026
EPS Estimate0.000.000.000.000.000.000.000.00----0.69-0.72-0.46-0.36-0.35-0.20-0.22-0.16-0.13-0.16-0.15-0.14
EPS Actual-0.010.010.060.090.090.080.02-0.01-0.05-0.12-0.13-1.56-0.60-0.21-0.40-0.40-0.33-0.23-0.87-0.050.03-0.16-
Surprise------------126.09%16.67%54.35%-11.11%-14.29%-65.00%-4.55%-443.75%61.54%118.38%-6.67%-
Timing----------After-hours-Pre-marketAfter-hoursPre-market-Pre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap270.31M
Enterprise Value296.01M
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.00
Price / Book47.00
EPS-1.35
Book Value0.107
Revenue (TTM)45.08M
Gross Profit (TTM)38.67M
EBITDA-29.95M
Profit Margin-62.59%
Operating Margin-86.03%
Return on Equity-496.21%
Return on Assets-36.75%
Shares Outstanding61.57M
Shares Float49.50M
Beta0.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 10.40
  • Strong Buy
    6
  • Buy
    2

Ownership Breakdown

Institutions
35.72%
Insiders
33.96%
Retail / Other
30.32%

Top Institutional Holders

  • First Light Asset Management, LLC
    6.55M10.64%
  • Awm Investment Company Inc
    2.08M3.38%
  • Nantahala Capital Management, LLC
    2.07M3.36%
  • BlackRock Inc
    1.50M2.44%
  • Vanguard Capital Management, LLC
    1.35M2.19%
  • Gilder Gagnon Howe & CO LLC
    888.51K1.44%
  • HPM Partners LLC
    787.27K1.28%
  • Geode Capital Management, LLC
    777.09K1.26%
  • White Pine Capital LLC
    547.58K0.89%
  • Thompson, Siegel & Walmsley LLC
    536.53K0.87%
  • Kennedy Capital Management Inc
    476.26K0.77%
  • Morgan Stanley - Brokerage Accounts
    393.91K0.64%
  • State Street Corp
    328.02K0.53%
  • Perkins Capital Management Inc
    230.10K0.37%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.14M1.85%
  • iShares Russell 2000 ETF
    1.10M1.79%
  • Fidelity Small Cap Index
    519.36K0.84%
  • iShares Russell 2000 Growth ETF
    453.63K0.74%
  • Vanguard Russell 2000 ETF
    274.63K0.45%
  • Fidelity Extended Market Index
    235.13K0.38%